Literature DB >> 24140751

Quantification of secretory leukocyte protease inhibitor (SLPI) in oral gargle specimens collected using mouthwash.

Christine M Pierce Campbell1, Wei Guan, Robert Sprung, John M Koomen, Michael T O'Keefe, Donna J Ingles, Martha Abrahamsen, Anna R Giuliano.   

Abstract

BACKGROUND: Secretory leukocyte protease inhibitor (SLPI) is an innate immunity-associated protein known to inhibit HIV transmission, and is thought to inhibit a variety of infectious agents, including human papillomaviruses (HPVs). We aimed to optimize an established ELISA-based SLPI quantification assay for use with oral gargle specimens collected using mouthwash, and to assess preliminary associations with age, smoking status, and alcohol intake.
METHODS: Oral gargle supernatants from 50 individuals were used to optimize the Human SLPI Quantikine ELISA Kit. Sample suitability was assessed and quality control analyses were conducted.
RESULTS: Salivary SLPI was successfully recovered from oral gargles with low intra-assay and high inter-individual variability. Initial measurements showed that salivary SLPI varied considerably across individuals, and that SLPI was inversely associated with age.
CONCLUSIONS: This optimized assay can be used to examine the role of SLPI in the acquisition of oral HPV and other infections.
© 2013. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CV; HNC; HPV; Immune system protein; Innate immunity; OD; Oral disease; Oral gargle; SLPI; Secretory leukocyte protease inhibitor; coefficients of variation.; head and neck cancer; human papillomavirus; optical density; secretory leukocyte protease inhibitor

Mesh:

Substances:

Year:  2013        PMID: 24140751      PMCID: PMC3990009          DOI: 10.1016/j.jim.2013.10.005

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  10 in total

1.  The relationship between secretory leukocyte protease inhibitor expression and Epstein-Barr virus status among patients with nasopharyngeal carcinoma.

Authors:  Ka-Po Tse; Chi-Sheng Wu; Chuen Hsueh; Kai-Ping Chang; Sheng-Po Hao; Yu-Sun Chang; Ngan-Ming Tsang
Journal:  Anticancer Res       Date:  2012-04       Impact factor: 2.480

2.  Secretory leukocyte protease inhibitor (SLPI) expression and tumor invasion in oral squamous cell carcinoma.

Authors:  Jie Wen; Nikolaos G Nikitakis; Risa Chaisuparat; Teresa Greenwell-Wild; Maria Gliozzi; Wenwen Jin; Azita Adli; Niki Moutsopoulos; Tanxia Wu; Gary Warburton; Sharon M Wahl
Journal:  Am J Pathol       Date:  2011-06       Impact factor: 4.307

3.  ELISA for quantitative measurement of low-molecular-weight bronchial protease inhibitor in human sputum.

Authors:  J A Kramps; C Franken; J H Dijkman
Journal:  Am Rev Respir Dis       Date:  1984-06

4.  Human papillomavirus and rising oropharyngeal cancer incidence in the United States.

Authors:  Anil K Chaturvedi; Eric A Engels; Ruth M Pfeiffer; Brenda Y Hernandez; Weihong Xiao; Esther Kim; Bo Jiang; Marc T Goodman; Maria Sibug-Saber; Wendy Cozen; Lihua Liu; Charles F Lynch; Nicolas Wentzensen; Richard C Jordan; Sean Altekruse; William F Anderson; Philip S Rosenberg; Maura L Gillison
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

Review 5.  Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-I.

Authors:  S M Wahl; T B McNeely; E N Janoff; D Shugars; P Worley; C Tucker; J M Orenstein
Journal:  Oral Dis       Date:  1997-05       Impact factor: 3.511

6.  The epidemiology of oral HPV infection among a multinational sample of healthy men.

Authors:  Aimee R Kreimer; Alessandro Villa; Alan G Nyitray; Martha Abrahamsen; Mary Papenfuss; Danelle Smith; Allan Hildesheim; Luisa L Villa; Eduardo Lazcano-Ponce; Anna R Giuliano
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-12-10       Impact factor: 4.254

7.  The level of secretory leukocyte protease inhibitor is decreased in metastatic head and neck squamous cell carcinoma.

Authors:  Christian Cordes; Robert Häsler; Christian Werner; Tibor Görögh; Christoph Röcken; Lena Hebebrand; W Martin Kast; Markus Hoffmann; Stefan Schreiber; Petra Ambrosch
Journal:  Int J Oncol       Date:  2011-04-14       Impact factor: 5.650

8.  Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism.

Authors:  Esra Fakioglu; Sarah S Wilson; Pedro M M Mesquita; Ehsan Hazrati; Natalia Cheshenko; John A Blaho; Betsy C Herold
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

9.  Human papillomavirus infection in head and neck cancer: the role of the secretory leukocyte protease inhibitor.

Authors:  Markus Hoffmann; Elgar S Quabius; Silke Tribius; Lena Hebebrand; Tibor Görögh; Gordana Halec; Tomas Kahn; Jürgen Hedderich; Christoph Röcken; Jochen Haag; Tim Waterboer; Markus Schmitt; Anna R Giuliano; W Martin Kast
Journal:  Oncol Rep       Date:  2013-03-05       Impact factor: 3.906

10.  The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection.

Authors:  Andrew W Woodham; Diane M Da Silva; Joseph G Skeate; Adam B Raff; Mark R Ambroso; Heike E Brand; J Mario Isas; Ralf Langen; W Martin Kast
Journal:  PLoS One       Date:  2012-08-22       Impact factor: 3.240

  10 in total
  6 in total

1.  Distribution and factors associated with salivary secretory leukocyte protease inhibitor concentrations.

Authors:  S Rahman; C M Pierce Campbell; B N Torres; M T O'Keefe; D J Ingles; L L Villa; R J Carvalho da Silva; R C Cintra; E Lazcano-Ponce; J Salmeron; M Quiterio; A R Giuliano
Journal:  Oral Dis       Date:  2016-08-17       Impact factor: 3.511

2.  Salivary secretory leukocyte protease inhibitor (SLPI) and head and neck cancer: The Cancer Prevention Study II Nutrition Cohort.

Authors:  Christine M Pierce Campbell; Anna R Giuliano; B Nelson Torres; Michael T O'Keefe; Donna J Ingles; Rebecca L Anderson; Lauren R Teras; Susan M Gapstur
Journal:  Oral Oncol       Date:  2016-02-24       Impact factor: 5.337

3.  Secretory Leukocyte Protease Inhibitor Expression and High-Risk HPV Infection in Anal Lesions of HIV-Positive Patients.

Authors:  Alcina F Nicol; Laurie L Brunette; Gerard J Nuovo; Beatriz Grinsztejn; Ruth K Friedman; Valdiléa G Veloso; Cynthia B Cunha; José R Coutinho; Cecilia Vianna-Andrade; Nathalia S Oliveira; Andrew W Woodham; Diane M DA Silva; W Martin Kast
Journal:  J Acquir Immune Defic Syndr       Date:  2016-09-01       Impact factor: 3.731

4.  Evaluation of HPV-16 and HPV-18 specific antibody measurements in saliva collected in oral rinses and merocel® sponges.

Authors:  Katherine H Parker; Troy J Kemp; Yuanji Pan; Zhen Yang; Anna R Giuliano; Ligia A Pinto
Journal:  Vaccine       Date:  2018-04-06       Impact factor: 3.641

5.  Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome.

Authors:  Brittney L Dickey; Bradley Sirak; Laura Martin-Gomez; Richard R Reich; Martha Abrahamsen; Kimberly Isaacs-Soriano; Christine H Chung; Anna R Giuliano
Journal:  PLoS One       Date:  2021-07-02       Impact factor: 3.240

6.  Quadrivalent Human Papillomavirus (HPV) Vaccine Induces HPV-Specific Antibodies in the Oral Cavity: Results From the Mid-Adult Male Vaccine Trial.

Authors:  Ligia A Pinto; Troy J Kemp; B Nelson Torres; Kimberly Isaacs-Soriano; Donna Ingles; Martha Abrahamsen; Yuanji Pan; Eduardo Lazcano-Ponce; Jorge Salmeron; Anna R Giuliano
Journal:  J Infect Dis       Date:  2016-08-10       Impact factor: 5.226

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.